Novel Approaches to Immunotherapy Rapidly Gaining Ground
OncoSec Medical, Inc.Expert is available to comment on the impending likely approval of Merck & Co.’s immuno-oncology drug, pembrolizumab, as a treatment for melanoma. According to Dr. Robert H. Pierce of OncoSec Medical, it is believed that 60 to 70 percent of patients with metastatic melanoma exhibit no response to anti-PD-1 immunotherapy that Merck is developing, so it could be useful to combine it with other forms of immunotherapy. One such alternate form is OncoSec’s ImmunoPulse, which delivers brief electrical pulses of DNA IL-12 and has shown in early studies to date to penetrate and destroy cancer cells.